目的：探讨康柏西普联合激光对糖尿病视网膜病变患者炎症因子、氧化应激水平及视网膜血流动力学的影响。

方法：选取2015-10/2017-02在我院诊治的糖尿病视网膜病变患者100例，随机分为对照组和观察组，每组50例。对照组给予激光治疗，观察组在对照组的基础上给予康柏西普治疗，之后对两组患者治疗前后临床疗效、炎症因子、氧化应激及视网膜血流动力学水平进行检测。

结果：治疗前两组患者的视力LogMAR值及视网膜厚度均无显著性差异(P>0.05)，治疗后两组患者的视力LogMAR值及视网膜厚度均显著降低，观察组患者治疗后视力LogMAR值为0.65±0.05，视网膜厚度为157.97±15.51μm，均较对照组显著降低，差异有统计学意义(P<0.05)； 两组患者治疗后，血清炎症因子IL-1β、IL-6及IL-8水平均较治疗前显著降低，观察组治疗后IL-1β、IL-6及IL-8水平分别为16.93±0.48ng/L、92.22±1.03pg/mL及0.33±0.06ng/L，显著低于对照组治疗后，差异有统计学意义(P<0.05)； 治疗后两组患者MDA、LHP及ROS水平均明显降低，且观察组患者治疗后MDA、LHP及ROS水平分别为4.16±0.21μmol/L、164.97±6.51μmol/L及261.15±14.44μmol/L，显著低于对照组治疗后，差异有统计学意义(P<0.05)； 治疗后两组患者PSV及EDV水平均明显升高，RI水平明显降低，观察组治疗后PSV及EDV水平分别为9.59±0.22cm/s及2.96±0.05cm/s，显著高于对照组治疗后，RI水平为0.66±0.04，显著低于对照组治疗后，差异有统计学意义(P<0.05)。

结论：康柏西普联合激光可有效提高糖尿病视网膜病变患者视力，降低视网膜厚度，降低炎症因子及氧化应激水平，改善视网膜血流动力学，疗效可靠。

METHODS: One hundred patients with diabetic retinopathy who were diagnosed and treated in our hospital from October 2015 to February 2017 were randomly divided into control group and observation group, 50 cases in each group. The control group was given laser treatment. The observation group was treated with conbercept on the basis of the control group. Afterwards, the clinical efficacy, inflammatory factors, oxidative stress and retinal hemodynamic level were tested before and after treatment of two groups of patients.

RESULTS: There was no significant difference in LogMAR value and retinal thickness between the two groups before treatment(P>0.05). After treatment, both LogMAR values of visual acuity and retinal thickness decreased significantly in the two groups. After treatment, the LogMAR value of visual acuity of the observation group was 0.65±0.05, the thickness of retina was 157.97±15.51μm, which was significantly lower than that of the control group(P<0.05). After treatment, the levels of IL-1β, IL-6 and IL-8 in serum were significantly lower than those before treatment. The levels of IL-1β, IL-6 and IL-8 of the observation group were 16.93±0.48ng/L, 92.22±1.03pg/mL and 0.33±0.06ng/L respectively, which were significantly lower than those of the control group after treatment(P<0.05). The levels of MDA, LHP and ROS in the two groups significantly decreased after treatment, and the levels of MDA, LHP and ROS in the observation group were 4.16±0.21μmol/L, 164.97±6.51μmol/L and 261.15±14.44μmol/L, which was significantly lower than that of the control group after treatment(P<0.05). After treatment, PSV and EDV levels in both groups significantly increased, and RI levels significantly decreased. The levels of PSV and EDV in the observation group were 9.59±0.22cm/s and 2.96±0.05cm/s, respectively, which were significantly higher than those in the control group. The RI level in the control group was 0.66±0.04, which was significantly lower than that in the control group(P<0.05).

CONCLUSION: Conbercept combined with laser can effectively improve the vision of patients with retinopathy, reduce retinal thickness, reduce the levels of inflammatory cytokines and oxidative stress, and improve retinal hemodynamics. The curative effect is reliable.